<DOC>
	<DOC>NCT00808418</DOC>
	<brief_summary>This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.</brief_summary>
	<brief_title>A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Inclusion Criteria Confirmed metastatic prostate cancer No more than one prior chemotherapy on which the disease progressed ECOG performance status of less than or equal to 2 Adequate bone marrow, renal and hepatic functions as defined in the protocol Neuropathy less than or equal to 2 Reliable venous access for frequent study drug infusions Exclusion Criteria Significant cardiovascular disease Known active brain metastases Subjects that have received treatment for other malignancies with in the past 5 years Other clinically significant uncontrolled conditions</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>castration</keyword>
	<keyword>refractory</keyword>
	<keyword>elesclomol</keyword>
	<keyword>sodium</keyword>
	<keyword>docetaxel</keyword>
	<keyword>prednisone</keyword>
</DOC>